Chr. Hansen Holding A/S (CHYHY)

OTCMKTS: CHYHY · Delayed Price · USD
18.11
-0.70 (-3.73%)
May 18, 2022 11:57 AM - Market open
Market Cap9.53B
Revenue (ttm)1.21B
Net Income (ttm)899.82M
Shares Out525.95M
EPS (ttm)1.68
PE Ratio10.78
Forward PE8.36
Dividend$0.52 (2.89%)
Ex-Dividend DateNov 24, 2021
Volume8,848
Open18.18
Previous Close18.82
Day's Range18.08 - 18.42
52-Week Range16.82 - 24.21
Beta0.15
AnalystsHold
Price Target19.65 (+8.5%)
Earnings Daten/a

About CHYHY

Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. It operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products ...

IndustrySpecialty Chemicals
Founded1874
CEOMauricio Graber
Employees3,702
Stock ExchangeOTCMKTS
Ticker SymbolCHYHY
Full Company Profile

Analyst Forecast

According to 20 analysts, the average rating for CHYHY stock is "Hold." The 12-month stock price forecast is 19.65, which is an increase of 8.48% from the latest price.

Price Target
$19.65
(8.48% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Chr. Hansen Holding A/S Interim Report Q2 2021/22

Company announcement no. 03/2022

1 month ago - GlobeNewsWire

Chr. Hansen Holding A/S Interim Report Q1 2021/22

January 13, 2022

4 months ago - GlobeNewsWire

Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S

Company announcement no. 14/2021 November 24, 2021. Please see attachment.

5 months ago - GlobeNewsWire

Chr. Hansen Holding A/S - Manager's transactions

Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364

6 months ago - GlobeNewsWire

Chr. Hansen Holding A/S Interim Report Q3 2020/21

July 8, 2021

10 months ago - GlobeNewsWire

Extraordinary dividend

Company announcement No. 7

1 year ago - GlobeNewsWire

Chr. Hansen Holding A/S Interim report Q2 2020/21

Continued strong organic growth momentum leads to upwards narrowing of full-year organic growth guidance

1 year ago - GlobeNewsWire

Chr. Hansen Holding A/S Interim report Q1 2020/21

Company Announcement No. 01

1 year ago - GlobeNewsWire

Chr. Hansen Holding A/S Full-year report - Statement of results 2019/20

Company Announcement No. 23/2020

1 year ago - GlobeNewsWire

Chr. Hansen Holding A/S enters into a definitive agreement to divest its Natural Colors business to EQT

Chr. Hansen Holding A/S has today entered into an agreement to divest its Natural Colors business to the EQT IX Fund for a cash consideration of 800 EUR million on cash and debt free basis. The transact...

1 year ago - GlobeNewsWire

Chr. Hansen Holding A/S acquires Jennewein Biotechnologie GmbH to enter and lead the high-growth Human Milk Oligosacc...

Chr. Hansen Holding A/S (“Chr. Hansen”) has today entered into an agreement to acquire all of the shares of Jennewein Biotechnologie GmbH (“Jennewein”), which is a leading player in the Human Milk Oligo...

1 year ago - GlobeNewsWire

UAS Laboratories LLC, a portfolio company of Lakeview Equity Partners, LLC, has been sold to Chr. Hansen Holding A/S

CHICAGO, July 28, 2020 /PRNewswire/ -- Lincoln International is pleased to announce that UAS Laboratories LLC, a portfolio company of Lakeview Equity Partners, LLC, has been sold to Chr. Hansen Holding ...

1 year ago - PRNewsWire

Chr. Hansen Holding A/S acquires UAS Laboratories LLC

Company Announcement No. 15/2020 - Chr. Hansen Holding A/S has today entered into an agreement with the owners of UAS Laboratories LLC (“UAS Labs”) to acquire 100% of the Wisconsin based B2B company spe...

1 year ago - GlobeNewsWire